The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, pose the next scalability challenge.
Hear about our venture into the development and manufacturing of viral vector gene therapies and how we are overcoming challenges and maintaining our commitment to our partners.
Explore case studies for neuromuscular degenerative indications, AAV technology and manufacturing, and strategies for navigating the regulatory environments in the U.S. and Europe.
Our development expertise across all gene therapy modalities (AAV, lentivirus, oncolytic virus, etc.) and proven clinical through commercial scale-up capabilities will provide full life cycle support of your life-saving therapeutic.
